Nuclear Receptor Platform

About KinCon biolabs

KinCon biolabs is an Austrian biotech startup pioneering a live-cell biosensor platform for drug discovery. Its core technology, the KinCon biosensor, enables real-time, high-content analysis of protein conformational changes—particularly for kinases, nuclear receptors, p53, and E3 ligases—in response to drug candidates. The platform aims to accelerate the identification of mutation-specific therapeutics, with an initial focus on neurodegenerative disorders and oncology. As a private, pre-revenue company, KinCon operates as a platform technology provider, serving pharmaceutical and biotech partners through research collaborations and services.

Therapeutic Areas